Cluster #1 (acute exacerbation) remains a highly active domain, with emerging keywords such as “PD-L1 expression” and “lung cancer surgery,” suggesting increasing integration of immune checkpoint research and perioperative strategies in clinical management. The gene discussed is CD274; the disease is lung carcinoma.